INCHEON, South Korea, Jan. 20, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), reported financial results for the fourth quarter and fiscal year 2025. "In 2025, Samsung Biologics delivered stable and resilient performance despite a highly uncertain global environment, supported by disciplined execution and strong demand," said John Rim, President and CEO of Samsung Biologics. "Consistent operations across our existing plants and ...